BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Luxdegalutamide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Luxdegalutamide\, from ClinicalTrials.gov
  estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06991556-10762@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT06991556)
DESCRIPTION:Luxdegalutamide\, phase 2.\nStudy: An Open-label Study of JSB46
 2 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients
  With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)\nEstimated prim
 ary completion: 3 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/luxdegalutamide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06991556
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174063-10762@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Luxdegalutamide: Phase 1 readout est. (NCT07174063)
DESCRIPTION:Luxdegalutamide\, phase 1.\nStudy: A Phase I Study of JSB462 (L
 uxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer\nEsti
 mated primary completion: 29 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/luxdegalutamide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07174063
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067140-10762@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:Luxdegalutamide: Phase 1/2 readout est. (NCT05067140)
DESCRIPTION:Luxdegalutamide\, phase 1/2.\nStudy: A Study of ARV-766 Given b
 y Mouth in Men With Metastatic Prostate Cancer\nEstimated primary completi
 on: 25 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/luxd
 egalutamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05067140
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047118-10762@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Luxdegalutamide: Phase 2 readout est. (NCT07047118)
DESCRIPTION:Luxdegalutamide\, phase 2\, Metastatic Castration-Resistant Pro
 state Cancer.\nStudy: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (1
 77Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resista
 nt Prostate Cancer (mCRPC)\nEstimated primary completion: 16 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/luxdegalutamide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07047118
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206056-10762@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20291109
DTEND;VALUE=DATE:20291110
SUMMARY:Luxdegalutamide: Phase 1/2 readout est. (NCT07206056)
DESCRIPTION:Luxdegalutamide\, phase 1/2.\nStudy: An Open-label Dose Escalat
 ion and Expansion\, Followed by a Phase II Study of Tulmimetostat (DZR123)
  and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Cast
 rate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)\nEstimated primary c
 ompletion: 9 November 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/luxdegalutamide#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07206056
URL:https://assetmemo.bio/drug/luxdegalutamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
